Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2019-04-09 Regulatory Filings
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Nuvec® Research update
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated '09 April 2019'. It explicitly states that the information is deemed inside information under MAR and is being published via a 'Regulatory Information Service'. The content discusses research updates, collaboration results (University of Adelaide), in-vitro/in-vivo inconsistencies, process improvements, and next steps for the company's product, Nuvec®. This structure—a formal announcement disseminated through an official regulatory news service (RNS) detailing operational and research updates—is characteristic of a general regulatory announcement rather than a comprehensive financial report (like 10-K or IR) or a specific event material (like AGM-R or CT). Since it is a formal, non-standard filing disseminated via RNS, the most appropriate classification is the general regulatory filing category.
2019-04-09 English
Verona Pharma Granted Key EU Patent Related to Late-stage COPD Clinical Candidate Ensifentrine
Regulatory Filings Classification · 1% confidence The document is a press release dated April 09, 2019, announcing that the European Patent Office granted an additional key patent related to their lead development candidate, ensifentrine. It discusses intellectual property protection, clinical trial progress, and commercial potential. This type of announcement, focusing on specific corporate developments (like patent grants or clinical updates) released via a news wire service (GLOBE NEWSWIRE), is typically classified as a general regulatory announcement or a specific update that doesn't fit the core financial reports (10-K, IR, ER). Since it is not a full financial report, earnings release, or a formal filing like a 10-K, and it details a specific corporate event (patent grant), it best fits the 'Regulatory Filings' (RNS) category as a general regulatory announcement, or potentially a Capital/Financing Update (CAP) if the patent was considered a key asset value driver, but RNS is the broader, safer fit for non-standard press releases detailing operational/IP news. Given the content is primarily an update on intellectual property and clinical progress, and it is structured as a standard press release, RNS (Regulatory Filings) is the most appropriate general classification for this type of market-sensitive, non-periodic disclosure.
2019-04-09 English
Grant of Options and RSUs and PDMR Dealings
Director's Dealing Classification · 1% confidence The document explicitly announces transactions involving 'directors and employees' of Verona Pharma, specifically detailing the grant of options, RSUs, and RADSUs. It includes a section titled 'PDMR Dealings' (Persons Discharging Managerial Responsibilities) and provides detailed transaction tables for executives like the CEO and CFO. This content directly relates to reporting personal share transactions by company directors and executives, which aligns perfectly with the definition of Director's Dealing.
2019-04-04 English
finnCap publishes initiation research
Report Publication Announcement Classification · 1% confidence The document is very short (2950 characters) and its primary purpose is to announce that the company's broker, finnCap, has initiated research coverage and that the research report is available via a portal. It explicitly states 'finnCap publishes initiation research' and provides contact details and boilerplate information, characteristic of a brief regulatory news service announcement. Since the document is an announcement about the publication of external research rather than the research itself, and it is distributed via RNS (indicated by the RNS Number and LSE footer), it fits best under the Report Publication Announcement (RPA) category, as it announces the availability of a report. However, given the context of RNS distribution and the nature of the announcement (a general update/news item not fitting other specific categories like DIV, DIRS, or ER), the Regulatory Filings (RNS) category is also a strong candidate. Since the core action is announcing the publication of a report/research, RPA is more specific than the general RNS fallback. I will select RPA based on the 'Menu vs Meal' rule applied to the announcement of external research.
2019-04-02 English
Poster presentation of Imperial College data
Environmental & Social Information Classification · 1% confidence The document begins with an 'RNS Number' and is dated March 28, 2019. It announces that data from a research collaboration is being presented as a poster at a symposium and provides a link to view the poster. The document concludes with a standard disclaimer stating, 'This information is provided by RNS, the news service of the London Stock Exchange.' This structure—a brief announcement referencing external material (a poster presentation) and originating from the RNS system—indicates a general regulatory announcement that doesn't fit the specific categories like ER, IR, or IP. Since it is a general regulatory announcement from the London Stock Exchange's news service (RNS), the most appropriate fallback category is Regulatory Filings (RNS). The document length (4248 chars) is short, but the content is a direct announcement of an event/data release, not just a pointer to a major report, making RNS more suitable than RPA.
2019-03-28 English
Verona Pharma to Present at H.C. Wainwright Global Life Sciences Conference
Regulatory Filings Classification · 1% confidence The document is a press release dated March 26, 2019, announcing that the management team of Verona Pharma plc will present at the H.C. Wainwright Global Life Sciences Conference on April 8th. It provides details about the CEO's presentation time and includes standard sections like 'About Verona Pharma plc' and 'Forward-Looking Statements'. This type of announcement, detailing management's participation in an external industry conference, is typically classified as an Investor Presentation (IP) if it were the presentation itself, or an announcement related to investor relations activities. Since it is an announcement about management presenting at a conference, it falls under the general category of investor communication, but the specific event is a presentation. However, looking at the definitions, it is not a formal Earnings Release (ER), nor is it a formal Investor Presentation (IP) document itself, but rather an announcement *about* a presentation. Given the context of investor communication regarding future events and company updates, and lacking a specific 'Conference Announcement' code, the closest fit among the provided options that relates to investor engagement and future outlook is Investor Presentation (IP), as it signals upcoming investor interaction, or potentially Regulatory Filings (RNS) as a general announcement. Since the core purpose is to inform investors about management's upcoming presentation and engagement, and it is not a formal report, the most appropriate classification for an announcement about management presenting at an investor conference is often grouped with investor-facing materials. Given the options, and recognizing this is an announcement about management engaging with investors, it is most closely related to Investor Presentation (IP) or a general Regulatory Filing (RNS). Since it is a specific announcement about management presenting, and not a general regulatory filing, I will lean towards the category that covers investor engagement materials. However, if we strictly follow the definitions, this is an announcement of management activity, which is not explicitly covered, but it is not a formal report. Since it is an announcement about management presenting, and not a formal report, I will classify it as a Regulatory Filing (RNS) as a general announcement of corporate activity that doesn't fit the specific report types, or potentially a proxy for Investor Presentation (IP). Given the content focuses on management presenting at a conference, which is a form of investor outreach, I will select RNS as the most neutral fit for an announcement that isn't a specific report type, but I acknowledge the strong link to investor relations.
2019-03-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.